Beacon Therapeutics’ gene therapy shows positive results for rare vision loss
Beacon Therapeutics reported positive topline results from its pivotal VISTA trial of laruparetigene zovaparvovec (laru-zova) in male patients with X-linked retinitis pigmentosa. The randomized, controlled Phase 2/3 study enrolled 85 males aged 12 to 48 and evaluated two subretinal doses (6.8 E+11 v
<p>Beacon Therapeutics reported positive topline results from its pivotal VISTA trial of laruparetigene zovaparvovec (laru-zova) in male patients with X-linked retinitis pigmentosa. The randomized, controlled Phase 2/3 study enrolled 85 males aged 12 to 48 and evaluated two subretinal doses (6.8 E+11 v</p>